February 25, 2026. Avelo AG is pleased to announce that results from a clinical study evaluating the AveloMask Kit for detection of Pseudomonas aeruginosa  in adults with Cystic Fibrosis (CF) were presented at the DZIF Annual Meeting in Bonn by researchers from Heidelberg University Hospital. The study assessed non-invasive exhaled breath aerosol sampling using the AveloMask Kit as an alternative to sputum collection. New, highly effective CFTR-modulator therapies significant

November 21, 2025. Avelo is pleased to share that partners from the CLIME Research Group at Stellenbosch University  presented the latest AveloMask Kit tuberculosis (TB) study results today at the Union Conference in Copenhagen, a leading global forum for TB and the world’s largest conference on lung health. A short video summarizing the study results is available here: The study showcases the feasibility and diagnostic potential of capturing Mycobacterium tuberculosis  from

October, 27, 2025. Avelo has successfully completed its annual ISO 13485 surveillance audit conducted by BSI Group. The audit confirmed that Avelo’s quality management system continues to meet all applicable regulatory requirements for the design, development, manufacture, and distribution of specimen receptacles supporting in-vitro diagnostic applications. Maintaining ISO 13485:2016 certification is a key milestone for medical device companies, ensuring compliance with inter

August 22, 2025. Avelo’s first peer-reviewed publication has been released in the Journal of Clinical Microbiology , presenting the...